Last reviewed · How we verify

tirofiban intracoronary bolus-only

Kosuyolu Heart Hospital · Phase 3 active Small molecule

tirofiban intracoronary bolus-only is a glycoprotein IIb/IIIa inhibitor Small molecule drug developed by Kosuyolu Heart Hospital. It is currently in Phase 3 development for Acute coronary syndrome, Unstable angina. Also known as: Aggrastat.

Tirofiban is a non-peptide antagonist of the glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation.

Tirofiban is a non-peptide antagonist of the glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation. Used for Acute coronary syndrome, Unstable angina.

At a glance

Generic nametirofiban intracoronary bolus-only
Also known asAggrastat
SponsorKosuyolu Heart Hospital
Drug classglycoprotein IIb/IIIa inhibitor
Targetglycoprotein IIb/IIIa receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

By binding to the glycoprotein IIb/IIIa receptor, tirofiban prevents the final common pathway of platelet aggregation, thereby reducing the risk of thrombotic complications in patients undergoing coronary interventions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about tirofiban intracoronary bolus-only

What is tirofiban intracoronary bolus-only?

tirofiban intracoronary bolus-only is a glycoprotein IIb/IIIa inhibitor drug developed by Kosuyolu Heart Hospital, indicated for Acute coronary syndrome, Unstable angina.

How does tirofiban intracoronary bolus-only work?

Tirofiban is a non-peptide antagonist of the glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation.

What is tirofiban intracoronary bolus-only used for?

tirofiban intracoronary bolus-only is indicated for Acute coronary syndrome, Unstable angina.

Who makes tirofiban intracoronary bolus-only?

tirofiban intracoronary bolus-only is developed by Kosuyolu Heart Hospital (see full Kosuyolu Heart Hospital pipeline at /company/kosuyolu-heart-hospital).

Is tirofiban intracoronary bolus-only also known as anything else?

tirofiban intracoronary bolus-only is also known as Aggrastat.

What drug class is tirofiban intracoronary bolus-only in?

tirofiban intracoronary bolus-only belongs to the glycoprotein IIb/IIIa inhibitor class. See all glycoprotein IIb/IIIa inhibitor drugs at /class/glycoprotein-iib-iiia-inhibitor.

What development phase is tirofiban intracoronary bolus-only in?

tirofiban intracoronary bolus-only is in Phase 3.

What are the side effects of tirofiban intracoronary bolus-only?

Common side effects of tirofiban intracoronary bolus-only include Bleeding, Thrombocytopenia, Anemia.

What does tirofiban intracoronary bolus-only target?

tirofiban intracoronary bolus-only targets glycoprotein IIb/IIIa receptor and is a glycoprotein IIb/IIIa inhibitor.

Related